1. Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

3. Number and Age-Adjusted Rate of Persons Aged ≥18 With Diagnosed Diabetes Who Began Treatment for End-Stage Renal Disease Attributed to Diabetes -- United States and Puerto Rico,

4. Incretin-based Agents

5. CV Safety of Incretin-based Therapies in Patients With T2D

8. CV Outcomes Studies With GLP-1 Agonists

9. Summary by Class: DPP-4 Inhibitors (Ongoing)

10. CV Outcomes Studies With SGLT2 Inhibitors

11. CV Outcomes Studies With Dual PPAR Agonists

12. Potential Pathophysiological Pathways of Insulin Leading to Hypertension

13. Mean Changes in Weight, Fitness, and CVD Risk Factors in ILI and DSE Groups and the Difference Between Groups Averaged Across 4 Years

15. ORIGIN Key Results

17. Diabetes as a Risk Factor for CV Events: Vascular Outcomes in T2D

18. Diabetes, Glucose, and CVD

19. Hyperglycemia on Admission Associated With Worse Outcomes

23. HPS: Subgroup Evaluation Shows Consistent Benefit in Patients With Diabetes Regardless of CVD

24. HPS: Consistent Benefit in Diabetic Patients Regardless of Baseline LDL-C

25. Multifactorial Management in Diabetes The Steno-2 Study -- 13 Years of Follow-up

26. Primary Prevention Trials With Aspirin in Diabetes

27. FREEDOM Trial: Inclusion Criteria

29. SAVOR-TIMI 53 Summary

30. SAVOR-TIMI 53 Summary

31. EXAMINE

32. EXAMINE

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)

36. Abbreviations (cont)